Sperling Oded
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Mol Genet Metab. 2006 Sep-Oct;89(1-2):14-8. doi: 10.1016/j.ymgme.2006.03.015. Epub 2006 May 5.
Hereditary renal hypouricemia (HRH) is an inborn error of renal membrane transport specific for uric acid, resulting in increased renal urate clearance associated with hypouricemia. Apparently in most HRH patients, the disorder is caused by loss of function mutations in the gene SLC22A12 coding for human urate transporter 1 (hURAT1), shown to control urate reabsorption in the proximal tubules. The small group of HRH patients with normal SLC22A12 may be affected with mutations in other not yet identified urate transporters. Patients affected with SLC22A12 mutations exhibit attenuated response of urinary urate excretion to pyrazinamide (PZA) and to probenecid (PBD) loading, attributed previously to reflect defective tubular presecretory urate reabsorption. HRH is inherited in an autosomal recessive mode. Most HRH patients are asymptomatic, but some may form renal tract stones and or be predisposed to exercise-induced acute renal failure.
遗传性低尿酸血症(HRH)是一种针对尿酸的肾膜转运先天性缺陷,导致与低尿酸血症相关的肾尿酸清除率增加。显然,在大多数HRH患者中,该疾病是由编码人尿酸转运蛋白1(hURAT1)的SLC22A12基因突变导致功能丧失引起的,hURAT1被证明可控制近端小管中的尿酸重吸收。一小部分SLC22A12正常的HRH患者可能受到其他尚未确定的尿酸转运蛋白突变的影响。受SLC22A12突变影响的患者对吡嗪酰胺(PZA)和丙磺舒(PBD)负荷的尿尿酸排泄反应减弱,以前认为这反映了肾小管分泌前尿酸重吸收缺陷。HRH以常染色体隐性模式遗传。大多数HRH患者无症状,但有些患者可能会形成尿路结石和/或易患运动诱发的急性肾衰竭。